405230-93-5

Basic information

• Product Name: 2-Chloro-5-fluoro-3,4-pyridinediamine
• Synonyms: 2-Chloro-5-fluoro-3,4-pyridinediamine;2-Chloro-5-fluoropyridine-3,4-diaMine;3,4-PyridinediaMine, 2-chloro-5-fluoro-;2-CHLORO-3,4-DIAMINO-5-FLUOROPYRIDINE
• CAS NO: 405230-93-5
• Molecular Formula: C₅H₅ClFN₃
• Molecular Weight: 161.56
• Mol File: 405230-93-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.562
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2-Chloro-5-fluoro-3,4-pyridinediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-fluoro-3,4-pyridinediamine(405230-93-5)
• EPA Substance Registry System: 2-Chloro-5-fluoro-3,4-pyridinediamine(405230-93-5)

Safety Data

• Hazardous Substances Data: 405230-93-5(Hazardous Substances Data)

Usage

General Description

2-Chloro-5-fluoro-3,4-pyridinediamine, also known as Tavaborole, is a chemical compound with the molecular formula C6H5ClFN3. It is a potent antifungal agent that is commonly used for the treatment of onychomycosis, a fungal infection of the nails. Tavaborole works by inhibiting protein synthesis in fungi, leading to their eventual death. It is commonly used in the form of a topical solution and has been found to be effective in treating various types of fungal infections, particularly those caused by dermatophytes. Tavaborole has a relatively low risk of adverse effects and has proven to be a valuable addition to the arsenal of antifungal medications available for the treatment of fungal infections.

Upstream product

• 405230-80-0 2-chloro-5-fluoro-4-nitropyridine-1-oxide 
• 405230-86-6 2-chloro-5-fluoro-4-nitraminopyridine 
• 89510-90-7 4-amino-2-chloro-5-fluoropyridine 
• 405230-79-7 2-chloro-5-fluoropyridine-1-oxide 
• 31301-51-6 2-chloro-5-fluoropyridine 
• 405230-90-2 4-amino-2-chloro-5-fluoro-3-nitropyridine 

Downstream Products

• 405230-97-9 4-chloro-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 1334411-83-4 4-bromo-2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 1334407-23-6 N-(2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-yl)cyclopropanecarboxamide 
• 1334407-22-5 2-(2,6-dichlorophenyl)-N-(2,6-dimethylpyrimidin-4-yl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-amine 
• 1334411-84-5 4-chloro-7-fluoro-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine 
• 405231-23-4 1-[(1-acetyloxy-1-ethoxy)methyl]-4-chloro-7-fluoroimidazo[4,5-c]pyridine 
• 405231-08-5 4-chloro-7-fluoro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 
• 202806-40-4 3-deaza-3-fluoro-adenosine 

Relevant articles and documents

IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.

Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents

Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogensubstituted analogues (51 and 52), and 2′,3′ -dihalogen- substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7μM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.